A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Ivosidenib (Primary)
- Indications Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Acronyms (PyramIDH)
- Sponsors Institut de Recherches Internationales Serviers
- 09 Jan 2025 According to Servier media release, Phase 3 PyramIDH clinical trial has been initiated, and sites are actively recruiting across the globe.
- 10 Dec 2024 Study design presented at the 66th American Society of Hematology Annual Meeting and Exposition.
- 10 Dec 2024 Status changed from not yet recruiting to recruiting.